A Case of Eosinophilic Pneumonia Successfully Treated with Suplatast Tosilate Alone

Watanabe, Naoto; Hirata, Akira; Makino, Sohei; Fukuda, Takeshi

doi:10.1159/000211380

Cited by 3 publications

(3 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In recent years, a few case reports have demonstrated the successful treatment of CEP with suplatast tosilate due to intolerance of hormone therapy. 14 It has also been reported that monoclonal antibody omalizumab has a significant effect in the treatment of CEP. 15 , 16 , 17 Monoclonal antibody omalizumab is an anti‐IgE antibody used in asthma and other allergic diseases.…”

Section: Discussionmentioning

confidence: 97%

“…Suplatast tosilate has antiasthmatic, anti‐inflammatory, and antifibrotic activities. In recent years, a few case reports have demonstrated the successful treatment of CEP with suplatast tosilate due to intolerance of hormone therapy 14 . It has also been reported that monoclonal antibody omalizumab has a significant effect in the treatment of CEP 15–17 .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical characteristics of patients with chronic eosinophilic pneumonia in a Chinese tertiary‐care hospital: A 6‐year retrospective study

Wang

et al. 2021

Clinical Respiratory J

View full text Add to dashboard Cite

Introduction: Chronic eosinophilic pneumonia (CEP) is a rare disease with unknown etiology. Due to lack of specificity of CEP symptoms, clinicians are not experienced in establishing its diagnosis. Objectives: To summarize the clinical data of CEP patients to improve the understanding of CEP and reduce misdiagnosis. Methods: Data of patients pathologically diagnosed with CEP in the PLA General Hospital between May 2013 and May 2019 were collected, and clinical manifestations, imaging characteristics, pathological features, and treatment were retrospectively analyzed.Results: Twenty patients, including 6 males and 14 females, were diagnosed with CEP. The average age was 47.0 AE 10.2 years. The main clinical manifestations were cough and dyspnea. The average duration of CEP was 15.5 AE 11.5 months. The average proportion of eosinophils in the peripheral blood was 18.9 AE 17.8%, and the average proportion of eosinophils in the bronchoalveolar lavage fluid was 41.5 AE 19.4%. The main imaging features were patchy shadows and consolidation shadows. The most common manifestations on bronchoscopic examination were congestion and edema of the bronchial mucosa. Two patients had granular protrusions of the endotracheal membrane. Histological examination indicated infiltration of numerous eosinophils. All patients improved after prednisone therapy. Conclusion: CEP onset is insidious, and clinical manifestations lack specificity. Typical imaging features are peripheral and subpleural distribution of lung infiltrates. Some patients have a normal proportion of eosinophils in the peripheral blood, but most have an increased number of eosinophils in the BALF, which contributes to CEP diagnosis. A biopsy is necessary when differential diagnosis is difficult. A systemic glucocorticoid is effective.

show abstract

Section: Discussionmentioning

confidence: 97%

Section: Discussionmentioning

confidence: 99%

Clinical characteristics of patients with chronic eosinophilic pneumonia in a Chinese tertiary‐care hospital: A 6‐year retrospective study

Wang

et al. 2021

Clinical Respiratory J

View full text Add to dashboard Cite

show abstract

“…In recent years, there were a few case reports of successful treatment of CEP by suplatast tosilate due to intolerance of hormone therapy [18]. Suplatast tosilate is mainly used to treat asthma and allergic rhinitis, which can reduce IgE synthesis by inhibiting the production of interleukin-4 by T cells.…”

Section: Discussionmentioning

confidence: 99%

Clinical Characteristics of 20 Patients with Chronic Eosinophilic Pneumonia: A 6-year Retrospective Study

Xu¹,

Wang²,

Zhang³

et al. 2020

Preprint

View full text Add to dashboard Cite

Abstract Background: Chronic eosinophilic pneumonia (CEP) is a rare disease and there are few systematic studies on the disease. We summarized the clinical and pathological data of CEP to improve the understanding of the disease, as well as to reduce misdiagnosis and mistreatment. Methods: The data of patients pathologically diagnosed as CEP in PLA General Hospital between May 2013 and May 2019 were collected, and the clinical manifestations, imaging characteristics, pathological features, treatment and prognosis were retrospectively analyzed. Results: There were 20 patients with CEP, including 6 males and 14 females. The average age at the time of diagnosis was 47.0 ± 10.2 (22-83) years, and the average course of disease was 15.5 ±11.5 (2-72) months. The main clinical manifestations were cough, dyspnea, expectoration, and shortness of breath, and often accompanied by fever, weight loss, and asthenia. 19 patients had elevated peripheral blood eosinophils, with the proportion of eosinophils ranging from 5.3-64.7%, and the absolute value of eosinophils ranging from 0.72-14.43×109/L. 18 patients had increased proportion of eosinophils in bronchoalveolar lavage fluid (BALF), ranging from 12-67%, with an average of 46%. The main imaging features were patchy shadows, consolidated shadows, and ground glass shadows. The histological examination of bronchial mucosal biopsy indicated eosinophilic infiltration in submucosal tissues and the pulmonary biopsy indicated a large number of eosinophils infiltration in alveolar cavity and septum as the main pathological changes of CEP. All of 20 patients were treated with glucocorticoid, and one of them relapsed during follow-up. Conclusions: The onset of CEP is insidious and the clinical manifestations are lack of specificity. Eosinophils increase in peripheral blood and BALF in most of CEP patients. The typical image is peripheral and subpleural distribution of lung infiltrates. The diagnosis of CEP depends on pathology, and glucocorticoid therapy is effective.

show abstract

Omalizumab Therapy for Allergic Diseases

Martinez-Tadeo¹,

Perez-Rodriguez²,

Almeida-Sanchez³

2013

Frontiers in Clinical Drug Research – Anti Allergy Agents

View full text Add to dashboard Cite

A Case of Eosinophilic Pneumonia Successfully Treated with Suplatast Tosilate Alone

Cited by 3 publications

References 59 publications

Clinical characteristics of patients with chronic eosinophilic pneumonia in a Chinese tertiary‐care hospital: A 6‐year retrospective study

Clinical characteristics of patients with chronic eosinophilic pneumonia in a Chinese tertiary‐care hospital: A 6‐year retrospective study

Clinical Characteristics of 20 Patients with Chronic Eosinophilic Pneumonia: A 6-year Retrospective Study

Omalizumab Therapy for Allergic Diseases

Contact Info

Product

Resources

About